Neoantigen Cancer Vaccines Industry Analysis Report 2025 with Tariff-Adjusted Forecasts and Analytics to 2030

Dublin, June 13, 2025 (GLOBE NEWSWIRE) — The “Neoantigen Cancer Vaccines – Global Strategic Business Report” has been added to ResearchAndMarkets.com’s offering.

The global market for Neoantigen Cancer Vaccines was valued at US$26.1 Million in 2024 and is projected to reach US$79.2 Million by 2030, growing at a CAGR of 20.3% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Neoantigen Cancer Vaccines market.

Report Features:

• Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
• In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
• Company Profiles: Coverage of players such as Agenus Inc., BioNTech SE, Candel Therapeutics, Genelux Corporation, and more.
• Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

The growth in the neoantigen cancer vaccines market is driven by several interlinked factors related to technological progress, precision medicine uptake, and oncology treatment innovation. A major growth catalyst is the rising demand for personalized therapies that minimize toxicity and maximize tumor-specific immune targeting. Neoantigen vaccines directly respond to this need, offering unprecedented specificity and a favorable safety profile.

End-use expansion across high-burden cancer types and integration into multimodal treatment regimens are accelerating clinical and commercial interest. The maturation of enabling technologies especially NGS, AI-based epitope prediction, and mRNA vaccine platforms is reducing production timelines and improving scalability. Regulatory agencies are also showing increasing openness to individualized therapeutics, with some neoantigen programs gaining fast-track and orphan drug designations, which further facilitate clinical translation.

Additionally, increased venture capital investment and biopharma collaborations are fueling R&D momentum. Academic-industry partnerships are helping build decentralized manufacturing capabilities, while government-sponsored precision medicine initiatives are embedding personalized immunotherapy within national cancer care frameworks. As clinical evidence continues to mount and manufacturing processes become more agile, neoantigen cancer vaccines are set to become a cornerstone of next-generation oncology treatment paradigms.

Key Insights:

• Market Growth: Understand the significant growth trajectory of the Personalized Neo-Antigen Vaccine segment, which is expected to reach US$52.5 Million by 2030 with a CAGR of a 22.3%. The Off-the Shelf Neoantigen Vaccine segment is also set to grow at 17.0% CAGR over the analysis period.
• Regional Analysis: Gain insights into the U.S. market, valued at $7.1 Million in 2024, and China, forecasted to grow at an impressive 27.6% CAGR to reach $18.9 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

• Detailed Market Analysis: Access a thorough analysis of the Global Neoantigen Cancer Vaccines Market, covering all major geographic regions and market segments.
• Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
• Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Neoantigen Cancer Vaccines Market.
• Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

• How is the Global Neoantigen Cancer Vaccines Market expected to evolve by 2030?
• What are the main drivers and restraints affecting the market?
• Which market segments will grow the most over the forecast period?
• How will market shares for different regions and segments change by 2030?
• Who are the leading players in the market, and what are their prospects?

Some of the 41 companies featured in this Neoantigen Cancer Vaccines market report include:

• Agenus Inc.
• BioNTech SE
• Candel Therapeutics
• Genelux Corporation
• Geneos Therapeutics
• GlaxoSmithKline plc (GSK)
• Grey Wolf Therapeutics
• HiFiBiO Therapeutics
• Immunovant, Inc.
• Moderna, Inc.
• Nouscom AG
• Personalis, Inc.
• Recombio
• SpliceBio
• Transgene S.A.
• Vaccibody AS
• Vaximm AG
• Vaxine Pty Ltd
• ViroTarg
• Y-mAbs Therapeutics, Inc.

This edition integrates the latest global trade and economic shifts as of June 2025 into comprehensive market analysis. Key updates include:

• Tariff and Trade Impact: Insights into global tariff negotiations across 180+ countries, with analysis of supply chain turbulence, sourcing disruptions, and geographic realignment. Special focus on 2025 as a pivotal year for trade tensions, including updated perspectives on the Trump-era tariffs.
• Adjusted Forecasts and Analytics: Revised global and regional market forecasts through 2030, incorporating tariff effects, economic uncertainty, and structural changes in globalization. Includes historical analysis since 2015.
• Strategic Market Dynamics: Evaluation of revised market prospects, regional outlooks, and key economic indicators such as population and urbanization trends.
• Innovation & Technology Trends: Latest developments in product and process innovation, emerging technologies, and key industry drivers shaping the competitive landscape.
• Competitive Intelligence: Updated global market share estimates for 2025, competitive positioning of major players (Strong/Active/Niche/Trivial), and refined focus on leading global brands and core players.
• Expert Insight & Commentary: Strategic analysis from economists, trade experts, and domain specialists to contextualize market shifts and identify emerging opportunities.
• Complimentary Update: Buyers receive a free July 2025 update with finalized tariff impacts, new trade agreement effects, revised projections, and expanded country-level coverage.

Key Attributes

MARKET OVERVIEW

• Influencer Market Insights
• World Market Trajectories
• Tariff Impact on Global Supply Chain Patterns
• Neoantigen Cancer Vaccines – Global Key Competitors Percentage Market Share in 2025 (E)
• Competitive Market Presence – Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)

MARKET TRENDS & DRIVERS

• Breakthroughs in Tumor Genomics and Next-Gen Sequencing Drive Development of Personalized Neoantigen Vaccines
• OEM Investment in mRNA and DNA Vaccine Platforms Strengthens Pipeline of Neoantigen-Based Therapies
• Growing Demand for Individualized Immunotherapy Supports Expansion of Custom Tumor-Specific Vaccines
• Rising Cancer Incidence and Unmet Clinical Need Accelerate Regulatory Support for Neoantigen Trials
• Push for Tumor-Agnostic Therapies Enhances Scope of Neoantigen Vaccines in Hard-to-Treat Cancers
• Growing Use of Personalized Cancer Vaccines in Combination With Immune Checkpoint Inhibitors Enhances Efficacy
• OEM Focus on AI and Bioinformatics Tools Improves Neoantigen Prediction and Immunogenicity Scoring
• Expansion of Global Cancer Vaccine Clinical Trials Drives Geographic Diversification of Neoantigen Research
• OEM Development of Off-the-Shelf Neoantigen Libraries Targets Common Cancer Mutations in Semi-Personalized Therapies

For more information about this report visit https://www.researchandmarkets.com/r/ugnulx

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

• Neoantigen Cancer Vaccines Market